0
USD
U.S. (TOLL FREE)
+1 (425) 388-2538
Automative

0
U.S. (TOLL FREE)
+1 (425) 388-2538

Global Non-invasive Prenatal Testing (NIPT) Market Forecast to 2025

Published Date: March 2019
|
Report Code: INFO-Othe-130
Home | Category |Health |Medical Facilities & Services |Medical Procedures
Global Noninvasive Prenatal Testing NIPT Market Forecast to 2025

Global Non-invasive Prenatal Testing (NIPT) Market Forecast to 2025

Code: INFO-Othe-130
Report
March 2019
83 Pages
Infoholic Research
Region: North America, Europe,
Description
Table of Content
Tables & Figures

Global Non-invasive Prenatal Testing (NIPT) Market: Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025
[83 pages report] This market research report includes a detailed segmentation of the global non-invasive prenatal testing market – By Application (Trisomy, Microdeletion Syndrome, and Other NIPT Applications), and By Region (North America, Europe, Asia Pacific, and Rest of the World).
Overview of the Global Non-invasive Prenatal Testing Market Research
Infoholic’s market research report predicts that the global non-invasive prenatal testing market will grow at a CAGR of 17.5% during the forecast period 2019–2025. The market has witnessed steady growth in the past few years and development in technology with the introduction of advanced products has increased the acceptance of non-invasive prenatal testing products in the market. The market is fueled by an upsurge in the number of newborns with chromosomal disorders due to the increasing number of late pregnancies and growing demand for non-invasive procedures for early diagnosis.

The global market continues to grow, and NIPT is among the most widely used techniques for detecting genetic disorders in the fetal stage, which will help in the proper management of disease during the initial period of the gestation. The field is getting revolutionized with the advancement in technology. Vendors are focusing on new product launches, product approvals, and targeting end-user's perspective. The market generates revenue from the key players operating in this field, and few of them include Illumina Inc., Laboratory Corporation of America Holdings, Natera Inc., F. Hoffmann-La Roche Ltd., and Beijing Genomics Institute.
According to Infoholic Research analysis, North America accounted for the largest share in the global non-invasive prenatal testing market in 2018 and will retain a high position during the forecast period. According to WHO estimation, the prevalence of Down syndrome is between 1 in 1,000 and 1 in 1,100 live births worldwide. The incidence of Down syndrome is 1 in 212 with the women age between 35 and 39 and the risk significantly increases with maternal age, i.e., above 45, the incidence rate is 1 in 33 newborns. But the risk rate is very low in younger women in the age group of 24–25 years with incidence rate reduced to 1 in 1429. The risk of aneuploidy also increases with maternal age with an incidence rate of 1 in 192 for women in the age group of 35 years and 1 in 66 in the age group up of 40. Favorable reimbursement policies, availability of advanced technologies, presence of prominent vendors, and an increase in the prevalence of genetic disorders will increase the adoption and demand for tests in this region. Asia Pacific is expected to grow at a high CAGR during the forecast period, owing to factors such as increasing awareness of early disease diagnosis, increasing healthcare expenditure, and presence of huge population base.
By Application:
• Trisomy
• Microdeletion Syndrome
• Other NIPT Applications
In 2018, the trisomy segment occupied the largest share and is expected to grow at a high CAGR during the forecast period. Increasing incidence of chromosomal anomalies coupled with advanced maternal age makes the segment the major shareholder in the global non-invasive prenatal testing market. Further, innovations in technology are likely to propel the growth of the segment during the forecast period.
By Regions:
• North America
• Europe
• APAC
• RoW
The global market is dominated by North America, followed by Europe and Asia Pacific. The US occupied the dominant share in the North American market due to the increasing adoption of high- and average-risk NIPT test, rising number of late pregnancies that increase the number of newborns with Down syndrome, no risk of miscarriage, and availability of the advanced tests due to the presence of dominant vendors in the region.
Non-Invasive Prenatal Testing Market Research Competitive Analysis – The global non-invasive prenatal testing market has massive growth opportunities in both developed and developing regions. The advancements of tests will increase the competition among vendors. The increased focus of diagnostics and biotechnology companies has led to an increase in deals related to non-invasive testing products due to its increasing popularity. 10x Genomics Inc. and Berry Genomics Co. Ltd. entered into a collaboration to further develop approaches for next-generation NIPT in January 2018. In early 2018, IONA test developed by Premaitha Health plc has been approved by Brazil's regulatory authority, Agência Nacional de Vigilância Sanitária, for sale in the country as an IVD. In late 2018, PerkinElmer’s Vanadis NIPT system obtained CE-IVD mark for commercialization and distribution in Europe and in other countries where CE-IVD mark is accepted. The key market vendors are focusing on increasing the product portfolio. There are few acquisitions in the last few years. Premaitha acquired Yourgene Bioscience in Taiwan in March 2017. In July 2017, Eurofins Scientific closed the acquisition of GATC Biotech AG and this transaction comprises the acquisition of 62.63% of the shares owned by GATC in LifeCodexx AG, one of the Europe’s specialists in NIPT. In addition, other leading players are focusing on hugely investing in R&D activities to develop new products to attain a maximum share in the market.
Key vendors:
• Natera Inc.
• Laboratory Corporation of America Holdings (LabCorp)
• Illumina Inc.
• F. Hoffmann-La Roche
• Beijing Genomics Institute
• LifeCodexx AG
• Quest Diagnostics
• Yourgene Health Plc
• Myriad Genetics Inc.
• NIPD Genetics
• PerkinElmer Inc.
• Next Biosciences (Pty) Limited
Key competitive facts:
• The market is highly competitive with all the players competing to gain market shares. Intense competition, rapid advancements in technology, frequent changes in government policies, and the prices are key factors that confront the market.
• The requirement of high initial investment, implementation, and maintenance cost in the market are also limiting the entry of new players.
Benefits – The report provides complete details about the adoption rate of non-invasive prenatal tests. Thus, the key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives in the upcoming years along with details of the pureplay companies entering the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals, and to analyze before investing or expanding the business in this market.
Key Takeaways:
• Understanding the potential market opportunity with precise market size and forecast data.
• A detailed market analysis focusing on the growth of the non-invasive prenatal testing industry.
• Factors influencing the growth of the non-invasive prenatal testing market.
• In-depth competitive analysis of dominant and pure-play vendors.
• Prediction analysis of the non-invasive prenatal testing industry in both developed and developing regions.
• Key insights related to major segments of the non-invasive prenatal testing market.
• Latest market trend analysis impacting the buying behavior of the consumers.

Table of Contents


1 INDUSTRY OUTLOOK 8
1.1 Industry overview 8
1.2 Total addressable market 8
1.3 Industry Trends 9
2 Report Outline 10
2.1 Report Scope 10
2.2 Report Summary 10
2.3 Research Methodology 11
2.4 Report Assumptions 11
3 Market Snapshot 13
3.1 Market Definition – Infoholic Research 13
3.2 Advantages of genetic testing 13
3.3 Disadvantage of genetic testing 13
3.4 Segmented Addressable Market (SAM) 13
3.5 Trends of the genetic testing market 14
3.6 Related Markets 15
3.6.1 Point-Of-Care Diagnostics 15
3.6.2 Liquid biopsy 15
3.6.3 Transplantation diagnostics 16
3.6.4 Cell-free DNA testing 16
4 Market Outlook 17
4.1 Funding Scenario 17
4.2 Market segmentation 18
4.3 PEST Analysis 18
4.4 Porter 5(Five) Forces 19
5 Market Characteristics 21
5.1 DRO – Global Genetic Testing Market Dynamics 21
5.1.1 Drivers 21
5.1.1.1 Increasing incidence of disease across the globe 21
5.1.1.2 Upsurge in the demand for personalized medicine 22
5.1.1.3 Growing emphasis on early disease detection 22
5.1.2 Opportunities 23
5.1.2.1 Upsurge in healthcare spending and growing healthcare awareness in emerging countries 23
5.1.2.2 Increase in collaborations 23
5.1.3 Restraints 24
5.1.3.1 High test cost 24
5.1.3.2 Ethical issues related to genetic testing 24
5.2 DRO – Impact Analysis 25
5.3 Key Stakeholders 26
6 Test Type: Market Size and Analysis 28
6.1 Overview 28
6.2 Diagnostic testing 29
6.3 Prenatal and newborn testing 30
6.4 Predictive and presymptomatic screening 31
6.5 Others 33
7 Regions: Market Size and Analysis 35
7.1 Overview 35
7.2 North America 36
7.3 Europe 38
7.4 Asia Pacific 39
7.5 Rest of the World 40
8 Competitive Landscape 43
8.1 Overview 43
9 Vendor Profiles 46
9.1 Qiagen N.V. 46
9.1.1 Overview 46
9.1.2 Geographic Presence 52
9.1.3 Business Focus 53
9.1.4 SWOT Analysis 54
9.1.5 Business Strategies 54
9.2 F. Hoffmann-La Roche Ltd 55
9.2.1 Overview 55
9.2.2 Business Units 58
9.2.3 Geographic Presence 58
9.2.4 Business Focus 59
9.2.5 SWOT Analysis 59
9.2.6 Business Strategies 60
9.3 ABBOTT LABORATORIES 61
9.3.1 Overview 61
9.3.2 Business Unit 64
9.3.3 Geographic Presence 65
9.3.4 Business Focus 66
9.3.5 SWOT Analysis 67
9.3.6 Business Strategy 67
9.4 Illumina, Inc. 68
9.4.1 Overview 68
9.4.2 Business Units 74
9.4.3 Geographic Presence 75
9.4.4 Business Focus 76
9.4.5 SWOT Analysis 76
9.4.6 Business Strategy 77
9.5 Quest Diagnostics 77
9.5.1 Overview 77
9.5.2 Business Units 82
9.5.3 Business Focus 83
9.5.4 SWOT Analysis 83
9.5.5 Business Strategy 84
10 Companies to Watch For 85
10.1 Natera, Inc. 85
10.1.1 Overview 85
10.2 Myriad Genetics 86
10.2.1 Overview 86
10.3 Bio-Rad Laboratories 88
10.3.1 Overview 88
10.3.2 Bio-Rad laboratories: Recent Developments 89
10.4 bioMerieux S.A. 90
10.4.1 Overview 90
10.4.2 BioMerieux S.A.: Recent Developments 90
10.5 Luminex Corporation 91
10.5.1 Overview 91
10.5.2 Luminex Corporation: Recent Developments 92
10.6 Cepheid (Danaher Corporation) 93
10.6.1 Overview 93
10.6.2 Cepheid (Danaher Corporation): Recent Developments 94
10.7 Laboratory Corporation of America Holdings 95
10.7.1 Overview 95
10.7.2 Laboratory Corporation of America Holdings: Recent Developments 96
11 Annexure 97
11.1 Abbreviations 97

 


"

 

List of Tables


TABLE 1 FUNDING SCENARIO 18
TABLE 2 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET REVENUE BY REGIONS, 2018–2025 ($MILLION) 34
TABLE 3 OTHER PROMINENT VENDORS IN THE NON-INVASIVE PRENATAL TESTING MARKET 41
TABLE 4 NATERA INC.: OFFERINGS 42
TABLE 5 NATERA INC.: RECENT DEVELOPMENTS 42
TABLE 6 ILLUMINA INC.: PRODUCT OFFERINGS 47
TABLE 7 ILLUMINA INC.: RECENT DEVELOPMENTS 47
TABLE 8 LABORATORY CORPORATION OF AMERICA HOLDINGS: OFFERINGS 56
TABLE 9 LABORATORY CORPORATION OF AMERICA HOLDINGS: RECENT DEVELOPMENTS 56
TABLE 10 F. HOFFMANN-LA ROCHE LTD.: PRODUCT OFFERINGS 61
TABLE 11 F. HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS 61
TABLE 12 BEIJING GENOMICS INSTITUTE: PRODUCT OFFERINGS 67
TABLE 13 BEIJING GENOMICS INSTITUTE: RECENT DEVELOPMENTS 67
TABLE 14 QUEST DIAGNOSTICS: SNAPSHOT 70
TABLE 15 QUEST DIAGNOSTICS: RECENT DEVELOPMENTS 70
TABLE 16 LIFECODEXX AG: SNAPSHOT 73
TABLE 17 LIFECODEXX AG: RECENT DEVELOPMENTS 73
TABLE 18 YOURGENE HEALTH PLC: SNAPSHOT 75
TABLE 19 YOURGENE HEALTH PLC: RECENT DEVELOPMENTS 75
TABLE 20 NIPD GENETICS: SNAPSHOT 76
TABLE 21 NIPD GENETICS: RECENT DEVELOPMENTS 76
TABLE 22 MYRIAD GENETICS INC.: SNAPSHOT 77
TABLE 23 MYRIAD GENETICS INC.: RECENT DEVELOPMENTS 77
TABLE 24 PERKINELMER INC.: SNAPSHOT 79
TABLE 25 PERKINELMER INC.: RECENT DEVELOPMENTS 79
TABLE 26 NEXT BIOSCIENCES (PTY) LIMITED: SNAPSHOT 80
TABLE 27 NEXT BIOSCIENCES (PTY) LIMITED: RECENT DEVELOPMENTS 80


"
List of Charts :

CHART 1 RESEARCH METHODOLOGY OF GLOBAL NON-INVASIVE PRENATAL TESTING MARKET 12
CHART 2 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET REVENUE, 2018–2025 ($MILLION) 15
CHART 3 SEGMENTATION OF GLOBAL NON-INVASIVE PRENATAL TESTING MARKET 18
CHART 4 PEST ANALYSIS OF GLOBAL NON-INVASIVE PRENATAL TESTING MARKET 19
CHART 5 PORTER 5 FORCES ON GLOBAL NON-INVASIVE PRENATAL TESTING MARKET 20
CHART 6 MARKET DYNAMICS – DRO ANALYSIS 22
CHART 7 DRO – IMPACT ANALYSIS OF GLOBAL NON-INVASIVE PRENATAL TESTING MARKET 25
CHART 8 KEY STAKEHOLDERS 26
CHART 9 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SHARE BY APPLICATION SEGMENTATION, 2018 (%) 28
CHART 10 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SHARE BY APPLICATION SEGMENTATION, 2025 (%) 28
CHART 11 TRISOMY MARKET FORECAST, 2018–2025 ($MILLION) 29
CHART 12 MICRODELETION SYNDROME MARKET FORECAST, 2018–2025 ($MILLION) 31
CHART 13 OTHER NIPT APPLICATIONS MARKET FORECAST, 2018–2025 ($MILLION) 32
CHART 14 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SHARE BY GEOGRAPHICAL SEGMENTATION, 2018 (%) 33
CHART 15 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SHARE BY GEOGRAPHICAL SEGMENTATION, 2025 (%) 33
CHART 16 NON-INVASIVE PRENATAL TESTING MARKET REVENUE IN NORTH AMERICA, 2018–2025 ($MILLION) 35
CHART 17 NON-INVASIVE PRENATAL TESTING MARKET REVENUE IN EUROPE, 2018–2025 ($MILLION) 36
CHART 18 NON-INVASIVE PRENATAL TESTING MARKET REVENUE IN ASIA PACIFIC, 2018–2025 ($MILLION) 38
CHART 19 NON-INVASIVE PRENATAL TESTING MARKET REVENUE IN REST OF THE WORLD, 2018–2025 ($MILLION) 39
CHART 20 NATERA INC.: OVERVIEW SNAPSHOT 44
CHART 21 NATERA INC.: GEOGRAPHIC PRESENCE 44
CHART 22 NATERA INC.: SWOT ANALYSIS 45
CHART 23 ILLUMINA INC.: OVERVIEW SNAPSHOT 52
CHART 24 ILLUMINA INC.: BUSINESS UNITS 52
CHART 25 ILLUMINA INC.: GEOGRAPHIC PRESENCE 53
CHART 26 ILLUMINA INC.: SWOT ANALYSIS 54
CHART 27 LABORATORY CORPORATION OF AMERICA HOLDINGS: OVERVIEW SNAPSHOT 57
CHART 28 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS UNITS 58
CHART 29 LABORATORY CORPORATION OF AMERICA HOLDINGS: GEOGRAPHIC PRESENCE 58
CHART 30 LABORATORY CORPORATION OF AMERICA HOLDINGS: SWOT ANALYSIS 59
CHART 31 F. HOFFMANN-LA ROCHE LTD.: OVERVIEW SNAPSHOT 62
CHART 32 F. HOFFMANN-LA ROCHE LTD.: BUSINESS UNITS 63
CHART 33 F. HOFFMANN-LA ROCHE LTD.: GEOGRAPHIC PRESENCE 64
CHART 34 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS 65
CHART 35 BEIJING GENOMICS INSTITUTE: SWOT ANALYSIS 68

 

 

Global Non-invasive Prenatal Testing (NIPT) Market: Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025
[83 pages report] This market research report includes a detailed segmentation of the global non-invasive prenatal testing market – By Application (Trisomy, Microdeletion Syndrome, and Other NIPT Applications), and By Region (North America, Europe, Asia Pacific, and Rest of the World).
Overview of the Global Non-invasive Prenatal Testing Market Research
Infoholic’s market research report predicts that the global non-invasive prenatal testing market will grow at a CAGR of 17.5% during the forecast period 2019–2025. The market has witnessed steady growth in the past few years and development in technology with the introduction of advanced products has increased the acceptance of non-invasive prenatal testing products in the market. The market is fueled by an upsurge in the number of newborns with chromosomal disorders due to the increasing number of late pregnancies and growing demand for non-invasive procedures for early diagnosis.

The global market continues to grow, and NIPT is among the most widely used techniques for detecting genetic disorders in the fetal stage, which will help in the proper management of disease during the initial period of the gestation. The field is getting revolutionized with the advancement in technology. Vendors are focusing on new product launches, product approvals, and targeting end-user's perspective. The market generates revenue from the key players operating in this field, and few of them include Illumina Inc., Laboratory Corporation of America Holdings, Natera Inc., F. Hoffmann-La Roche Ltd., and Beijing Genomics Institute.
According to Infoholic Research analysis, North America accounted for the largest share in the global non-invasive prenatal testing market in 2018 and will retain a high position during the forecast period. According to WHO estimation, the prevalence of Down syndrome is between 1 in 1,000 and 1 in 1,100 live births worldwide. The incidence of Down syndrome is 1 in 212 with the women age between 35 and 39 and the risk significantly increases with maternal age, i.e., above 45, the incidence rate is 1 in 33 newborns. But the risk rate is very low in younger women in the age group of 24–25 years with incidence rate reduced to 1 in 1429. The risk of aneuploidy also increases with maternal age with an incidence rate of 1 in 192 for women in the age group of 35 years and 1 in 66 in the age group up of 40. Favorable reimbursement policies, availability of advanced technologies, presence of prominent vendors, and an increase in the prevalence of genetic disorders will increase the adoption and demand for tests in this region. Asia Pacific is expected to grow at a high CAGR during the forecast period, owing to factors such as increasing awareness of early disease diagnosis, increasing healthcare expenditure, and presence of huge population base.
By Application:
• Trisomy
• Microdeletion Syndrome
• Other NIPT Applications
In 2018, the trisomy segment occupied the largest share and is expected to grow at a high CAGR during the forecast period. Increasing incidence of chromosomal anomalies coupled with advanced maternal age makes the segment the major shareholder in the global non-invasive prenatal testing market. Further, innovations in technology are likely to propel the growth of the segment during the forecast period.
By Regions:
• North America
• Europe
• APAC
• RoW
The global market is dominated by North America, followed by Europe and Asia Pacific. The US occupied the dominant share in the North American market due to the increasing adoption of high- and average-risk NIPT test, rising number of late pregnancies that increase the number of newborns with Down syndrome, no risk of miscarriage, and availability of the advanced tests due to the presence of dominant vendors in the region.
Non-Invasive Prenatal Testing Market Research Competitive Analysis – The global non-invasive prenatal testing market has massive growth opportunities in both developed and developing regions. The advancements of tests will increase the competition among vendors. The increased focus of diagnostics and biotechnology companies has led to an increase in deals related to non-invasive testing products due to its increasing popularity. 10x Genomics Inc. and Berry Genomics Co. Ltd. entered into a collaboration to further develop approaches for next-generation NIPT in January 2018. In early 2018, IONA test developed by Premaitha Health plc has been approved by Brazil's regulatory authority, Agência Nacional de Vigilância Sanitária, for sale in the country as an IVD. In late 2018, PerkinElmer’s Vanadis NIPT system obtained CE-IVD mark for commercialization and distribution in Europe and in other countries where CE-IVD mark is accepted. The key market vendors are focusing on increasing the product portfolio. There are few acquisitions in the last few years. Premaitha acquired Yourgene Bioscience in Taiwan in March 2017. In July 2017, Eurofins Scientific closed the acquisition of GATC Biotech AG and this transaction comprises the acquisition of 62.63% of the shares owned by GATC in LifeCodexx AG, one of the Europe’s specialists in NIPT. In addition, other leading players are focusing on hugely investing in R&D activities to develop new products to attain a maximum share in the market.
Key vendors:
• Natera Inc.
• Laboratory Corporation of America Holdings (LabCorp)
• Illumina Inc.
• F. Hoffmann-La Roche
• Beijing Genomics Institute
• LifeCodexx AG
• Quest Diagnostics
• Yourgene Health Plc
• Myriad Genetics Inc.
• NIPD Genetics
• PerkinElmer Inc.
• Next Biosciences (Pty) Limited
Key competitive facts:
• The market is highly competitive with all the players competing to gain market shares. Intense competition, rapid advancements in technology, frequent changes in government policies, and the prices are key factors that confront the market.
• The requirement of high initial investment, implementation, and maintenance cost in the market are also limiting the entry of new players.
Benefits – The report provides complete details about the adoption rate of non-invasive prenatal tests. Thus, the key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives in the upcoming years along with details of the pureplay companies entering the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals, and to analyze before investing or expanding the business in this market.
Key Takeaways:
• Understanding the potential market opportunity with precise market size and forecast data.
• A detailed market analysis focusing on the growth of the non-invasive prenatal testing industry.
• Factors influencing the growth of the non-invasive prenatal testing market.
• In-depth competitive analysis of dominant and pure-play vendors.
• Prediction analysis of the non-invasive prenatal testing industry in both developed and developing regions.
• Key insights related to major segments of the non-invasive prenatal testing market.
• Latest market trend analysis impacting the buying behavior of the consumers.

Read More

Table of Contents


1 INDUSTRY OUTLOOK 8
1.1 Industry overview 8
1.2 Total addressable market 8
1.3 Industry Trends 9
2 Report Outline 10
2.1 Report Scope 10
2.2 Report Summary 10
2.3 Research Methodology 11
2.4 Report Assumptions 11
3 Market Snapshot 13
3.1 Market Definition – Infoholic Research 13
3.2 Advantages of genetic testing 13
3.3 Disadvantage of genetic testing 13
3.4 Segmented Addressable Market (SAM) 13
3.5 Trends of the genetic testing market 14
3.6 Related Markets 15
3.6.1 Point-Of-Care Diagnostics 15
3.6.2 Liquid biopsy 15
3.6.3 Transplantation diagnostics 16
3.6.4 Cell-free DNA testing 16
4 Market Outlook 17
4.1 Funding Scenario 17
4.2 Market segmentation 18
4.3 PEST Analysis 18
4.4 Porter 5(Five) Forces 19
5 Market Characteristics 21
5.1 DRO – Global Genetic Testing Market Dynamics 21
5.1.1 Drivers 21
5.1.1.1 Increasing incidence of disease across the globe 21
5.1.1.2 Upsurge in the demand for personalized medicine 22
5.1.1.3 Growing emphasis on early disease detection 22
5.1.2 Opportunities 23
5.1.2.1 Upsurge in healthcare spending and growing healthcare awareness in emerging countries 23
5.1.2.2 Increase in collaborations 23
5.1.3 Restraints 24
5.1.3.1 High test cost 24
5.1.3.2 Ethical issues related to genetic testing 24
5.2 DRO – Impact Analysis 25
5.3 Key Stakeholders 26
6 Test Type: Market Size and Analysis 28
6.1 Overview 28
6.2 Diagnostic testing 29
6.3 Prenatal and newborn testing 30
6.4 Predictive and presymptomatic screening 31
6.5 Others 33
7 Regions: Market Size and Analysis 35
7.1 Overview 35
7.2 North America 36
7.3 Europe 38
7.4 Asia Pacific 39
7.5 Rest of the World 40
8 Competitive Landscape 43
8.1 Overview 43
9 Vendor Profiles 46
9.1 Qiagen N.V. 46
9.1.1 Overview 46
9.1.2 Geographic Presence 52
9.1.3 Business Focus 53
9.1.4 SWOT Analysis 54
9.1.5 Business Strategies 54
9.2 F. Hoffmann-La Roche Ltd 55
9.2.1 Overview 55
9.2.2 Business Units 58
9.2.3 Geographic Presence 58
9.2.4 Business Focus 59
9.2.5 SWOT Analysis 59
9.2.6 Business Strategies 60
9.3 ABBOTT LABORATORIES 61
9.3.1 Overview 61
9.3.2 Business Unit 64
9.3.3 Geographic Presence 65
9.3.4 Business Focus 66
9.3.5 SWOT Analysis 67
9.3.6 Business Strategy 67
9.4 Illumina, Inc. 68
9.4.1 Overview 68
9.4.2 Business Units 74
9.4.3 Geographic Presence 75
9.4.4 Business Focus 76
9.4.5 SWOT Analysis 76
9.4.6 Business Strategy 77
9.5 Quest Diagnostics 77
9.5.1 Overview 77
9.5.2 Business Units 82
9.5.3 Business Focus 83
9.5.4 SWOT Analysis 83
9.5.5 Business Strategy 84
10 Companies to Watch For 85
10.1 Natera, Inc. 85
10.1.1 Overview 85
10.2 Myriad Genetics 86
10.2.1 Overview 86
10.3 Bio-Rad Laboratories 88
10.3.1 Overview 88
10.3.2 Bio-Rad laboratories: Recent Developments 89
10.4 bioMerieux S.A. 90
10.4.1 Overview 90
10.4.2 BioMerieux S.A.: Recent Developments 90
10.5 Luminex Corporation 91
10.5.1 Overview 91
10.5.2 Luminex Corporation: Recent Developments 92
10.6 Cepheid (Danaher Corporation) 93
10.6.1 Overview 93
10.6.2 Cepheid (Danaher Corporation): Recent Developments 94
10.7 Laboratory Corporation of America Holdings 95
10.7.1 Overview 95
10.7.2 Laboratory Corporation of America Holdings: Recent Developments 96
11 Annexure 97
11.1 Abbreviations 97

 


"

 

Read More

List of Tables


TABLE 1 FUNDING SCENARIO 18
TABLE 2 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET REVENUE BY REGIONS, 2018–2025 ($MILLION) 34
TABLE 3 OTHER PROMINENT VENDORS IN THE NON-INVASIVE PRENATAL TESTING MARKET 41
TABLE 4 NATERA INC.: OFFERINGS 42
TABLE 5 NATERA INC.: RECENT DEVELOPMENTS 42
TABLE 6 ILLUMINA INC.: PRODUCT OFFERINGS 47
TABLE 7 ILLUMINA INC.: RECENT DEVELOPMENTS 47
TABLE 8 LABORATORY CORPORATION OF AMERICA HOLDINGS: OFFERINGS 56
TABLE 9 LABORATORY CORPORATION OF AMERICA HOLDINGS: RECENT DEVELOPMENTS 56
TABLE 10 F. HOFFMANN-LA ROCHE LTD.: PRODUCT OFFERINGS 61
TABLE 11 F. HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS 61
TABLE 12 BEIJING GENOMICS INSTITUTE: PRODUCT OFFERINGS 67
TABLE 13 BEIJING GENOMICS INSTITUTE: RECENT DEVELOPMENTS 67
TABLE 14 QUEST DIAGNOSTICS: SNAPSHOT 70
TABLE 15 QUEST DIAGNOSTICS: RECENT DEVELOPMENTS 70
TABLE 16 LIFECODEXX AG: SNAPSHOT 73
TABLE 17 LIFECODEXX AG: RECENT DEVELOPMENTS 73
TABLE 18 YOURGENE HEALTH PLC: SNAPSHOT 75
TABLE 19 YOURGENE HEALTH PLC: RECENT DEVELOPMENTS 75
TABLE 20 NIPD GENETICS: SNAPSHOT 76
TABLE 21 NIPD GENETICS: RECENT DEVELOPMENTS 76
TABLE 22 MYRIAD GENETICS INC.: SNAPSHOT 77
TABLE 23 MYRIAD GENETICS INC.: RECENT DEVELOPMENTS 77
TABLE 24 PERKINELMER INC.: SNAPSHOT 79
TABLE 25 PERKINELMER INC.: RECENT DEVELOPMENTS 79
TABLE 26 NEXT BIOSCIENCES (PTY) LIMITED: SNAPSHOT 80
TABLE 27 NEXT BIOSCIENCES (PTY) LIMITED: RECENT DEVELOPMENTS 80


"
List of Charts :

CHART 1 RESEARCH METHODOLOGY OF GLOBAL NON-INVASIVE PRENATAL TESTING MARKET 12
CHART 2 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET REVENUE, 2018–2025 ($MILLION) 15
CHART 3 SEGMENTATION OF GLOBAL NON-INVASIVE PRENATAL TESTING MARKET 18
CHART 4 PEST ANALYSIS OF GLOBAL NON-INVASIVE PRENATAL TESTING MARKET 19
CHART 5 PORTER 5 FORCES ON GLOBAL NON-INVASIVE PRENATAL TESTING MARKET 20
CHART 6 MARKET DYNAMICS – DRO ANALYSIS 22
CHART 7 DRO – IMPACT ANALYSIS OF GLOBAL NON-INVASIVE PRENATAL TESTING MARKET 25
CHART 8 KEY STAKEHOLDERS 26
CHART 9 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SHARE BY APPLICATION SEGMENTATION, 2018 (%) 28
CHART 10 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SHARE BY APPLICATION SEGMENTATION, 2025 (%) 28
CHART 11 TRISOMY MARKET FORECAST, 2018–2025 ($MILLION) 29
CHART 12 MICRODELETION SYNDROME MARKET FORECAST, 2018–2025 ($MILLION) 31
CHART 13 OTHER NIPT APPLICATIONS MARKET FORECAST, 2018–2025 ($MILLION) 32
CHART 14 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SHARE BY GEOGRAPHICAL SEGMENTATION, 2018 (%) 33
CHART 15 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SHARE BY GEOGRAPHICAL SEGMENTATION, 2025 (%) 33
CHART 16 NON-INVASIVE PRENATAL TESTING MARKET REVENUE IN NORTH AMERICA, 2018–2025 ($MILLION) 35
CHART 17 NON-INVASIVE PRENATAL TESTING MARKET REVENUE IN EUROPE, 2018–2025 ($MILLION) 36
CHART 18 NON-INVASIVE PRENATAL TESTING MARKET REVENUE IN ASIA PACIFIC, 2018–2025 ($MILLION) 38
CHART 19 NON-INVASIVE PRENATAL TESTING MARKET REVENUE IN REST OF THE WORLD, 2018–2025 ($MILLION) 39
CHART 20 NATERA INC.: OVERVIEW SNAPSHOT 44
CHART 21 NATERA INC.: GEOGRAPHIC PRESENCE 44
CHART 22 NATERA INC.: SWOT ANALYSIS 45
CHART 23 ILLUMINA INC.: OVERVIEW SNAPSHOT 52
CHART 24 ILLUMINA INC.: BUSINESS UNITS 52
CHART 25 ILLUMINA INC.: GEOGRAPHIC PRESENCE 53
CHART 26 ILLUMINA INC.: SWOT ANALYSIS 54
CHART 27 LABORATORY CORPORATION OF AMERICA HOLDINGS: OVERVIEW SNAPSHOT 57
CHART 28 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS UNITS 58
CHART 29 LABORATORY CORPORATION OF AMERICA HOLDINGS: GEOGRAPHIC PRESENCE 58
CHART 30 LABORATORY CORPORATION OF AMERICA HOLDINGS: SWOT ANALYSIS 59
CHART 31 F. HOFFMANN-LA ROCHE LTD.: OVERVIEW SNAPSHOT 62
CHART 32 F. HOFFMANN-LA ROCHE LTD.: BUSINESS UNITS 63
CHART 33 F. HOFFMANN-LA ROCHE LTD.: GEOGRAPHIC PRESENCE 64
CHART 34 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS 65
CHART 35 BEIJING GENOMICS INSTITUTE: SWOT ANALYSIS 68

 

 

Read More
SELECT A FORMAT
Added to Cart

Single User

Electronic (PDF)
$2750
This license allows only one user to access the PDF.

Site License

Electronic (PDF)
$3500
This license allows all the users of an enterprise residing in one location to access the PDF

Enterprise License

Electronic (PDF)
$4500
This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)

RELATED REPORTS

Global Surgical Imaging Devices Market Professional Survey Report 2019
Global Surgical Imaging Devices Market Professional Survey Report 2019

Global Surgical Imaging Devices Market Professional Survey Report 2019

120 Pages
Type: Report
Code: QYRE-Auto-32G338
Wed Nov 06 00:00:00 UTC 2019

Add to Cart

Global Chlamydia Infection Diagnostics and Therapeutics Market Professional Survey Report 2019
Global Chlamydia Infection Diagnostics and Therapeutics Market Professional Survey Report 2019

Global Chlamydia Infection Diagnostics and Therapeutics Market Professional Survey Report 2019

120 Pages
Type: Report
Code: QYRE-Auto-10H571
Wed Nov 06 00:00:00 UTC 2019

Add to Cart

Global Biopsy Devices Market Professional Survey Report 2019
Global Biopsy Devices Market Professional Survey Report 2019

Global Biopsy Devices Market Professional Survey Report 2019

120 Pages
Type: Report
Code: QYRE-Auto-19D549
Wed Nov 06 00:00:00 UTC 2019

Add to Cart

Global Cart Based Ultrasonic Dissection Devices Market Professional Survey Report 2019
Global Cart Based Ultrasonic Dissection Devices Market Professional Survey Report 2019

Global Cart Based Ultrasonic Dissection Devices Market Professional Survey Report 2019

120 Pages
Type: Report
Code: QYRE-Auto-30N317
Wed Nov 06 00:00:00 UTC 2019

Add to Cart

0 Items
X
No items in the cart.
$0.0